Search
Veracyte Inc
VCYTAdd to Watchlist
53.210USD
-0.420-0.78%
Close 06/22, 16:00（ET）Quotes delayed by 15 min
4.22BMarket Cap
47.72P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-22The current earnings forecast score of Veracyte Inc is 8.50, ranking 109 out of 389 in the Biotechnology & Medical Research industry. The average price target is 48.00, with a high of 57.00 and a low of 43.00.
Analyst Rating
Based on
12
analysts
Buy
Current Rating
49.364
Target Price
-7.96%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
560
Total
5
Median
6
Average
Company name
Ratings
Analysts
Veracyte Inc
VCYT
12
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Veracyte Inc's expected revenue for the next quarter?
Veracyte Inc's expected revenue is 144.44M.
What is Veracyte Inc's price target?
Analysts forecast that Veracyte Inc's price target is USD 48.00, with the highest forecast at USD 57.00 and the lowest forecast at USD 43.00.
How have Veracyte IncVCYT's recent earnings per share performed?
The market expectation was USD 0.36, while Veracyte IncVCYT's earnings per share (EPS) for the previous quarter was USD 0.52. EPS for the next quarter is expected at USD 0.24.
What is the analyst rating for Veracyte Inc?
Based on the ratings of Veracyte Inc's stock from 12 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
